---
category: news
title: "New Alzheimer’s drug slows cognitive decline – and may be available as early as next year"
excerpt: "So is the benefit worth the risk and cost? Lecanemab slowed the rate of cognitive decline in people with mild cognitive impairment and early-stage Alzheimer’s disease by 27% over 18 months."
publishedDateTime: 2022-10-05T08:14:00Z
originalUrl: "https://theconversation.com/new-alzheimers-drug-slows-cognitive-decline-and-may-be-available-as-early-as-next-year-191627"
webUrl: "https://theconversation.com/new-alzheimers-drug-slows-cognitive-decline-and-may-be-available-as-early-as-next-year-191627"
ampWebUrl: "https://theconversation.com/amp/new-alzheimers-drug-slows-cognitive-decline-and-may-be-available-as-early-as-next-year-191627"
cdnAmpWebUrl: "https://theconversation-com.cdn.ampproject.org/c/s/theconversation.com/amp/new-alzheimers-drug-slows-cognitive-decline-and-may-be-available-as-early-as-next-year-191627"
type: article

provider:
  name: The Conversation
  domain: theconversation.com

topics:
  - Microsoft AI
  - AI

secured: "V6iX63WqBVTmIoO30xK8bf+dV8DCzuUG9qzyqSZ/O5xmNklRpW6ShOlfFGuBmgFvFJp8vGB3TKZK2+NPsrqizWbz6g2/PyhMQcADKfmDoi7x8fuLqhpnN7wd9L66Lg0VvzEYQVnY4p/7rFwUFEU2KtcfoFdEa73MoHZsnxOZvbZgkq9JfXiUOKHCmMnb8cFqooDUE52p1Gbq3nVDgXngpb+/1idxCjG0wuApyNBa6uYYvCpljkHSCRrG5zkmLyr7Flxuexn708vMJIDTcP4iQBpN4Gn7GurX5LgpX7wiTH6pqCRiZ3Z8XIaPeHdksJVAPF/stRQbcLSLr5OvDuCROVdnULVLlTJ6ExCWEGm78vU=;dB175XQCwJL6ysiZbiLLVw=="
---

